Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Guardant Health, Inc. - Common Stock
(NQ:
GH
)
97.10
-0.37 (-0.38%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 18, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Guardant Health, Inc. - Common Stock
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
19
20
Next >
Guardant Health to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
December 20, 2023
From
Guardant Health, Inc.
Via
Business Wire
Blood-Based Colorectal Cancer CRC Screening Market Likely to Benefit From FDA's Panel Surprise Advisory Possibility: Analyst
↗
December 20, 2023
Tuesday, Guardant Health Inc (NASDAQ: GH) announced that the FDA's Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is tentatively scheduled to review the premarket...
Via
Benzinga
S&P 500, Nasdaq Set For Weaker Open As 'FOMO' Rally Cools: Analyst Says Only 'Black Swan Could Upset Santa's Sleigh' Now
↗
December 20, 2023
Bond yields remain contained, providing a reason for traders to maintain their investments in stocks.
Via
Benzinga
Topics
Stocks
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
December 19, 2023
Via
Benzinga
What 7 Analyst Ratings Have To Say About Guardant Health
↗
December 13, 2023
Via
Benzinga
7 Analysts Have This to Say About Guardant Health
↗
November 13, 2023
Via
Benzinga
Earnings Scheduled For November 6, 2023
↗
November 06, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.
Via
Benzinga
The Latest Analyst Ratings for Guardant Health
↗
October 20, 2023
Via
Benzinga
Guardant Health Announces Tentative Date of FDA Advisory Panel Review of Shield™ Blood Test
December 19, 2023
From
Guardant Health, Inc.
Via
Business Wire
Cancer Research UK and Guardant Health Launch Collaboration to Advance Cancer Research and Clinical Development Activities
December 04, 2023
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health to present data at San Antonio Breast Cancer Symposium demonstrating utility of liquid biopsy in biomarker identification, therapy selection and residual disease detection
November 30, 2023
From
Guardant Health, Inc.
Via
Business Wire
Why Guardant Health Stock Popped Again Today
↗
September 28, 2023
Wall Street loves this unprofitable biotech.
Via
The Motley Fool
Jim Cramer: Buy This Financial Stock, 'It's Up Substantially From Where It Was In The Spring'
↗
November 28, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he remains a buyer of SoFi Technologies, Inc. (NASDAQ: SOFI).
Via
Benzinga
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 15, 2023
From
Guardant Health, Inc.
Via
Business Wire
Why Is Cancer Blood Test-Focused Guardant Health Stock Trading Lower Today?
↗
November 15, 2023
Guardant Health Inc (NASDAQ: GH) shares are falling after the company announced it intends to appeal its verdict in the U.S.
Via
Benzinga
Guardant Health to Appeal Federal District Court Verdict
November 15, 2023
From
Guardant Health, Inc.
Via
Business Wire
Cancer Test Firm Guardant Health Posts Smaller Than Expected Q3 Loss, Lifts Annual Sales Outlook
↗
November 07, 2023
Guardant Health Inc (NASDAQ: GH) reported Q3 revenue of $143 million, up 22% Y/Y, beating the consensus of $137.37 million
Via
Benzinga
Guardant Health Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance
November 06, 2023
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health to Participate in Upcoming November Investor Conferences
November 03, 2023
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health, Flatiron Health Announce Integration of Guardant Genomic Profiling Tests Into OncoEMR® Platform
October 31, 2023
From
Guardant Health, Inc.
Via
Business Wire
Bull Of The Day: NeoGenomics
↗
October 24, 2023
NeoGenomics is a small-cap provider of cancer genetics diagnostics. They boast one of the most comprehensive oncology-focused testing menus in the world to help physicians diagnose and treat cancer.
Via
Talk Markets
First results from PEGASUS trial reported at ESMO show promise for use of liquid biopsy to guide adjuvant treatment of colon cancer
October 23, 2023
From
Guardant Health, Inc.
Via
Business Wire
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
October 17, 2023
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NASDAQ:GH),(NASDAQ:NTRA),(NYSE:DGX),(NASDAQ:NEO) EQNX::TICKER_END
Via
FinancialNewsMedia
Guardant Health to Report Third Quarter 2023 Financial Results on November 6, 2023
October 16, 2023
From
Guardant Health, Inc.
Via
Business Wire
1 Beaten-Down Healthcare Stock to Buy and Hold For 10 Years
↗
October 11, 2023
This company's fight against a deadly disease could pay off.
Via
The Motley Fool
Which Is the Better Cancer-Testing Healthcare Stock: Exact Sciences or Guardant Health?
↗
October 08, 2023
The oncology diagnostic companies are looking for better solutions in early cancer diagnosis.
Via
The Motley Fool
Why Guardant Health Stock Jumped 15% This Week
↗
September 28, 2023
The precision oncology leader benefited from a pair of positive analyst notes this week. Here's what investors need to know.
Via
The Motley Fool
Guardant Health Has 'Underlying Business Strength' Says This Bullish Analyst
↗
September 27, 2023
Shares of Guardant Health Inc (NASDAQ: GH) climbed during the premarket trading session and morning on Wednesday.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023
↗
September 28, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023
↗
September 27, 2023
Via
Benzinga
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
19
20
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.